Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Deceleration capacity is associated with acute respiratory distress syndrome in COVID-19

Lars Mizera, Dominik Rath, Anna Schoellmann, Alvaro Petersen-Uribe, Alban Avdiu, Monika Zdanyte, Philippa Jaeger, David Heinzmann, Karin Müller, Meinrad Gawaz, Christian Eick, MD,*, Martin Duckheim

A R T I C L E   I N F O

Article History:
Received 20 March 2021
Revised 25 June 2021
Accepted 28 July 2021
Available online 2 August 2021

Keywords:
Deceleration capacity
COVID-19
Prognosis
Cardiac autonomic dysfunction
ARDS

A B S T R A C T

Background: Acute respiratory distress syndrome (ARDS) is considered the main cause of COVID-19 associated morbidity and mortality. Early and reliable risk stratification is of crucial clinical importance in order to identify persons at risk for developing a severe course of disease. Deceleration capacity (DC) of heart rate as a marker of cardiac autonomic function predicts outcome in persons with myocardial infarction and heart failure. We hypothesized that reduced modulation of heart rate may be helpful in identifying persons with COVID-19 at risk for developing ARDS.

Methods: We prospectively enrolled 60 consecutive COVID-19 positive persons presenting at the University Hospital of Tübingen. Arterial blood gas analysis and 24 h-Holter ECG recordings were performed and analyzed at admission. The primary end point was defined as development of ARDS with regards to the Berlin classification.

Results: 61.7% (37 of 60 persons) developed an ARDS. In persons with ARDS DC was significantly reduced when compared to persons with milder course of infection (3.2 ms vs. 6.6 ms, \( p < 0.001 \)). DC achieved a good discrimination performance (AUC = 0.76) for ARDS in COVID-19 persons. In a multivariate analysis, decreased DC was associated with the development of ARDS.

Conclusion: Our data suggest a promising role of DC to risk stratification in COVID-19.

© 2021 Elsevier Inc. All rights reserved.

I N T R O D U C T I O N

The current worldwide pandemic of the 2019 coronavirus disease (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) poses a significant threat to global health and economy. The clinical presentation varies widely among individuals from mild afebrile respiratory symptoms to severe illness causing acute respiratory distress syndrome (ARDS).\(^1\) Approximately 5% of infected persons require admission to an intensive care unit and approximately 12% of hospitalized COVID-19 persons receive mechanical ventilation.\(^2\) Prediction models for both prognosis and clinical course of COVID-19 are urgently required to identify persons at high risk of developing severe ARDS requiring mechanical ventilation. The quick COVID-19 severity index has been recently postulated as a risk score for short-term respiratory deterioration by assessing respiratory rate, oxygen saturation and oxygen flow rate.\(^4\) Current data suggest, however, that reliable prediction models are missing.\(^5\)

Therefore, further tools to support medical decision making are of great interest, especially in the setting of an emergency department or in an outpatient area. Heart rate variability analysis is a non-invasive, objective method assessing the sympathetic and vagal balance of the autonomic nervous system. Reduced heart rate deceleration capacity (DC) indicates impaired cardiac vagal modulations.\(^6\) DC has already been proved to be a powerful predictor of mortality in persons with myocardial infarction, heart failure, cancer, aortic stenosis, syncope, stroke and pneumonia.\(^6\)–\(^12\) Recently, a retrospective, observational case series emphasized direct and indirect affection of the central nervous system in COVID-19 persons with respiratory insufficiency.\(^13\) In the current study, we postulate that impaired DC provides prognostic information in persons with COVID-19.

M E T H O D S

S T U D Y   D E S I G N ,   S E T T I N G   A N D   P A R T I C I P A N T S

This prospective study was conducted in the Department of Cardiology, Angiology and Cardiovascular Medicine at the University
Hospital of Tuebingen, Germany. 60 consecutive COVID-19 positive persons were enrolled between March and April 2020. Inclusion criteria consisted of diagnosis of COVID-19 infection and sinus rhythm. During the first pandemic wave, a plethora of patients with mild to severe symptoms was hospitalized. SARS-CoV-2 was isolated from nasal and pharyngeal specimens by real-time reverse transcriptase polymerase chain reaction. The study was approved by the local Ethics Committee (238/2018B02) and complies with the declaration of Helsinki and the Good Clinical Practice Guidelines. Written informed consent was obtained from all persons or their legal representatives.

**Measurements**

Oxygen saturation and routine blood samples were obtained at hospital admission. If progressive dyspnea, oxygen requirement or reduced oxygen saturation <97% occurred, arterial blood gas analysis was performed. Additional arterial blood gas analysis was completed when patients showed relevant clinical worsening of their symptoms or oxygen insufflation was required. We determined ARDS by the ratio of partial pressure of oxygen in blood to fraction of inhaled oxygen (PaO2/FiO2). In this sense, ARDS was classified as mild (PaO2/FiO2 >200 mmHg, but <300 mmHg), moderate (PaO2/FiO2 >100 mmHg, but <200 mmHg) and severe (PaO2/FiO2 is <100 mmHg) according to the Berlin Definition of ARDS. Oxygen delivery devices such as nasal cannulas or venturi masks were used in non-ventilated persons to increase the FiO2 up to 60% based on known equipment standards. With a nasal cannula, the FiO2 increases by approximately 4% for every additional liter of oxygen flow provided. For example, a flow rate at 1L/min is able to increase the FiO2 to 24%, 3L/min to 32% and 6L/min up to 44%.

Persons received a 24 h-ECG Holter recording within 24 h after admission to the isolation ward. DC was automatically assessed from a 24 h-ECG Holter (Getemed CardioMem CM 3000SM 24 h Holter ECG Recorder) according to validated technologies. Briefly, sequences of RR intervals were processed by a signal processing algorithm called phase-rectified signal averaging (PRSA). RR intervals longer than their precursors are identified as so-called anchors. Segments with certain length surrounding the anchors are aligned and averaged to obtain the PRSA signal. The DC is acquired by quantifying the central amplitude of the PRSA signal by Haar-wavelet analysis. The DC can be considered as integral of all deceleration-related fluctuations during the selected period of observation. We only used the first 10 min of the ECG recordings for analysis of at least 200 anchors. In case of low signal quality, the observation period was extended to a maximum of 30 min until 200 anchors were identified. ECG recordings with noisy, low-quality signals were excluded using a validated algorithm. According to Bauer et al., a DC ≤ 4.5 ms might be associated with high risk of mortality.

**Outcomes**

We defined a composite of mild, moderate and/or severe ARDS during hospitalization as the primary endpoint.

**Analysis**

All statistical analyses were performed using SPSS version 26.0 2019 (SPSS Inc., Chicago IL). Non-normally distributed data was compared using Mann-Whitney U-Test. Chi-squared cross-tabulations were used to analyze qualitative data. Data was presented as mean ± standard deviation. Univariate and multivariate binary logistic regression analyses were used to evaluate associations between patient characteristics, laboratory results at admission and DC in terms of development of ARDS. The confidence interval was set to 95% and a p-value of ≤ 0.05 was considered significant. Receiver operating characteristic (ROC) curves were used to assess the sensitivity and specificity of DC for prediction of ARDS after admission to ED due to COVID-19. The overall discriminatory capacity of the test is estimated by the area under the ROC curve. Values of 1.0 indicate excellent and values of 0.5 imply missing discrimination. Values ranging from 0.7 to 0.8 represent good discrimination.

**Results**

**Characteristics of study participants**

60 persons with COVID-19 infection requiring hospitalization underwent 24 h-ECG Holter recording. Baseline characteristics, medical history and outcome of the overall cohort are presented in Table 1.

**Main results**

The incidence of ARDS was 61.7% (37 of 60 persons), with an intrahospital mortality of 5.0% (3 of 60 persons). Persons with ARDS matched by age (69.1 years vs. 63.3 years, p = 0.058), sex (21 males vs 15 males, p = 0.515) and body mass index (29.6 kg/m² vs. 27.6 kg/m², p = 0.412) when compared to the non-ARDS group. Hypertension as a comorbidity was more frequent in the ARDS group (p = 0.007). ARDS persons had a mean (± SD) PaO2/FiO2 of 178 ± 58 mmHg, 24 persons (64.9%) developed moderate to severe ARDS and 17 out of 37 ARDS persons (45.9%) required intubation. The mean timespan between DC measurement at isolation ward and admission to the ICU was 3.6 ± 4.6 days. Table 2 compares ARDS and non-ARDS persons in detail. There were no differences with regard to medication with possible impact on DC, such as beta-blockers or prevalence of diabetes between the two groups. Further characteristics comparing ARDS and non-ARDS persons are presented in Table 2. One person suffered from congestive heart failure (CHF).

We found DC to be significantly lower in persons with ARDS compared to non-ARDS persons (3.2 ± 2.2 ms vs. 6.6 ± 6.1 ms; p < 0.001, OR=0.7; 95% CI, 0.5–0.9; p = 0.005). Persons with ARDS were more likely to show a reduced DC <4.5 ms (ARDS 75.7% vs. non-ARDS 34.8%, p = 0.003). Furthermore, in ARDS persons, levels of troponin I, D-dimers, C-reactive protein and LDH levels were significantly higher and lymphocytes significantly lower when compared to non-ARDS persons.

COVID-19 persons with hypertension as a comorbidity had a increased risk of developing ARDS (OR=4.7; 95% CI, 1.5–14.9; p = 0.009). Additionally, univariate analysis indicated an association with ARDS in COVID-19 persons for the following factors: DC (OR=0.7; 95% CI, 0.5–0.9; p = 0.005), troponin I (OR=1.1; 95% CI, 1.0–1.2; p = 0.047) and LDH levels (OR=1.0; 95% CI, 1.0–1.01; Table 1)

| Age, years (mean ± SD) | 66.9 (± 13.4) |
| Male, n (%) | 36 (60.0) |
| Body mass index (mean ± SD) | 28.9 (5.7) |
| Medical history, n (%) |  
| Known coronary artery disease | 14 (23.3) |
| Congestive heart failure | 1 (1.7) |
| Chronic kidney disease | 6 (10.0) |
| Hypertension | 41 (68.3) |
| Diabetes mellitus | 11 (18.3) |
| Chronic obstructive pulmonary disease | 5 (8.3) |
| Immunosuppression | 6 (10.0) |
| Active Smoker | 1 (1.7) |
| Obesity | 14 (23.3) |
| Outcome, n (%) |  
| Admission to ICU | 19 (31.7) |
| Mechanical Ventilation | 17 (28.3) |
| Death | 2 (3.3) |
with COVID-19 infection. DC may be helpful to characterize persons in a more advanced disease stage of COVID-19 and therefore may be used as a marker of advanced disease. 

Severe respiratory failure with development of ARDS is a potential complication of COVID-19 infection. Previous reports also consider severe ARDS to be responsible for the majority of COVID-19 associated morbidity and mortality. Prognostic markers that help to distinguish persons at risk for severe ARDS are urgently needed to establish proper treatment strategies. Coagulation abnormalities and myocardial injury were found to be prevalent in COVID-19 positive persons and to be predictive of adverse outcomes. These studies identified higher levels of the myocardial distress marker troponin I, as well as higher levels of D-dimers, C-reactive protein and LDH on admission being highly predictive for respiratory insufficiency during the course of the COVID-19 disease. In line with these papers, we also found higher levels of troponin I and LDH in the ARDS group. Interestingly, persons in the ARDS group were more likely to suffer from hypertension.

As an early marker for progressive disease, we propose calculation of the DC. DC provides information regarding the cardiac autonomic function. The mechanisms of compromised DC are various and related to altered sympathovagal balance, reduced neuro-humoral function. The mechanisms of compromised DC are various and related to altered sympathovagal balance, reduced neuro-humoral function. The major findings of the current study are: Compromised DC was associated with an increased risk of developing ARDS in persons with COVID-19 infection. DC may be helpful to characterize persons in a more advanced disease stage of COVID-19 and therefore may be used as a marker of advanced disease.

Table 2
Baseline characteristics stratified according to the primary endpoint.

| Variable                  | Non-ARDS (n = 23) | ARDS (n = 37) | p value |
|---------------------------|-------------------|---------------|---------|
| Age, years (mean ± SD)    | 63.9 (±13.9)      | 69.1 (±12.8)  | 0.058   |
| Male, n (%)               | 15 (65.2)         | 21 (56.8)     | 0.515   |
| Body mass index (mean ± SD)| 27.6 (5.5)       | 29.6 (5.8)    | 0.412   |

**Medical History, n (%)**

| Variable                  | Non-ARDS (n = 23) | ARDS (n = 37) | p value |
|---------------------------|-------------------|---------------|---------|
| Hypertension              | 11 (47.8)         | 30 (81.1)     | 0.007   |
| Chronic kidney disease    | 3 (13.0)          | 11 (29.7)     | 0.137   |
| Chronic obstructive pulmonary disease | 5 (22.7) | 5 (13.5) | 0.066   |
| Immunosuppression         | 3 (13.0)          | 3 (8.1)       | 0.536   |
| Active smoker             | 1 (4.3)           | 0 (0.0)       | 0.213   |
| Obesity                   | 5 (22.7)          | 9 (24.3)      | 0.889   |

**Laboratory values at admission, mean ± SD**

| Variable                  | Non-ARDS (n = 23) | ARDS (n = 37) | p value |
|---------------------------|-------------------|---------------|---------|
| Leucocytes (1000/μl)      | 5.2 (±2.6)        | 6.5 (±2.4)    | 0.102   |
| Lymphocytes (1000/μl)     | 0.9 (±0.3)        | 0.6 (±0.3)    | 0.015   |
| Creatinine (mg/dl)        | 1.7 (±2.2)        | 1.1 (±0.7)    | 0.570   |
| D-dimers (μg/ml)          | 0.9 (±1.0)        | 3.2 (±6.7)    | 0.001   |
| C-reactive protein (mg/dl)| 5.4 (±6.8)        | 8.8 (±6.1)    | 0.007   |
| Troponin I (ng/l)         | 7.7 (±6.4)        | 13.3 (±65.6)  | 0.007   |
| NT-pro-BNP (ng/l)         | 532 (±1312)       | 2444 (±6267)  | 0.088   |
| LDH (U/l)                 | 257 (±86)         | 354 (±149)    | 0.003   |

**Medication at admission, n (%)**

| Variable                  | Non-ARDS (n = 23) | ARDS (n = 37) | p value |
|---------------------------|-------------------|---------------|---------|
| Oral anticoagulation       | 1 (4.3)           | 1 (4.0)       | 1.000   |
| ACE/ARB                   | 9 (40.9)          | 18 (64.3)     | 0.009   |
| Calcium channel blockers  | 7 (31.8)          | 7 (23.3)      | 0.496   |
| Beta-blockers             | 9 (40.0)          | 12 (40.9)     | 0.947   |
| Statins                   | 9 (40.9)          | 14 (46.7)     | 0.680   |
| ASS                       | 5 (22.7)          | 10 (33.3)     | 0.404   |
| P2Y12 inhibitors          | 1 (4.3)           | 0 (0.0)       | 0.238   |

**Severity of ARDS, n (%)**

| Variable                  | Non-ARDS (n = 23) | ARDS (n = 37) | p value |
|---------------------------|-------------------|---------------|---------|
| Mild                      | 13 (21.7)         | 15 (21.7)     | 0.515   |
| Moderate                  | 19 (31.7)         | 19 (29.7)     | 0.137   |
| Severe                    | 5 (8.3)           | 13 (21.7)     | 0.496   |

**Main study parameter**

| Variable                  | Non-ARDS (n = 23) | ARDS (n = 37) | p value |
|---------------------------|-------------------|---------------|---------|
| Nadir PaO2/FiO2 (mmHg)    | 411 ± 72          | 178 ± 58      | <0.001  |
| Intrahospital days        | 7.6 ± 8.6         | 16.0 ± 10.9   | 0.003   |
| Deceleration capacity (ms, mean ± SD) | 6.6 ± 6.1 | 3.2 ± 2.2 | <0.001  |
| Deceleration capacity -4.5 ms, n (%) | 8 (34.8%) | 8 (22.7%) | 0.003   |
| Deceleration capacity -2.5 ms, n (%) | 2 (8.7%)    | 2 (5.5%)     | 0.003   |

| Variable                  | Hazard Ratio (95% CI) | p-value |
|---------------------------|-----------------------|---------|
| DC                        | 0.7 (0.5–0.9)         | 0.005   |
| Hypertension              | 4.7 (1.5–14.9)        | 0.009   |
| D-dimers                  | 1.9 (0.9–3.7)         | 0.010   |
| C-reactive protein        | 1.1 (1.0–1.2)         | 0.004   |
| Troponin I                | 1.1 (1.0–1.2)         | 0.009   |
| LDH                       | 1.0 (1.0–1.01)        | 0.009   |

As an early marker for progressive disease, we propose calculation of the DC. DC provides information regarding the cardiac autonomic function. The mechanisms of compromised DC are various and related to altered sympathovagal balance, reduced neuro-humoral function. The major findings of the current study are: Compromised DC was associated with an increased risk of developing ARDS in persons with COVID-19 infection. DC may be helpful to characterize persons in a more advanced disease stage of COVID-19 and therefore may be used as a marker of advanced disease.

As an early marker for progressive disease, we propose calculation of the DC. DC provides information regarding the cardiac autonomic function. The mechanisms of compromised DC are various and related to altered sympathovagal balance, reduced neuro-humoral function. The mechanisms of compromised DC are various and related to altered sympathovagal balance, reduced neuro-humoral function. The mechanisms of compromised DC are various and related to altered sympathovagal balance, reduced neuro-humoral function. The major findings of the current study are: Compromised DC was associated with an increased risk of developing ARDS in persons with COVID-19 infection. DC may be helpful to characterize persons in a more advanced disease stage of COVID-19 and therefore may be used as a marker of advanced disease.

As an early marker for progressive disease, we propose calculation of the DC. DC provides information regarding the cardiac autonomic function. The mechanisms of compromised DC are various and related to altered sympathovagal balance, reduced neuro-humoral function. The mechanisms of compromised DC are various and related to altered sympathovagal balance, reduced neuro-humoral function. The major findings of the current study are: Compromised DC was associated with an increased risk of developing ARDS in persons with COVID-19 infection. DC may be helpful to characterize persons in a more advanced disease stage of COVID-19 and therefore may be used as a marker of advanced disease.

As an early marker for progressive disease, we propose calculation of the DC. DC provides information regarding the cardiac autonomic function. The mechanisms of compromised DC are various and related to altered sympathovagal balance, reduced neuro-humoral function. The mechanisms of compromised DC are various and related to altered sympathovagal balance, reduced neuro-humoral function. The major findings of the current study are: Compromised DC was associated with an increased risk of developing ARDS in persons with COVID-19 infection. DC may be helpful to characterize persons in a more advanced disease stage of COVID-19 and therefore may be used as a marker of advanced disease.
making in the outpatient area, help to establish treatment strategies and avoid unnecessary hospitalization for low-risk persons. In this sense, both material and personal resources might be preserved and exposition of health care personal can be reduced.

Various limitations of our study need to be mentioned. First, due to the small cohort of COVID-19 infected persons in this study, the present data should be considered hypothesis generating and multi-variate analysis needs cautious interpretation. Further verification in prospective control studies is required. Second, the proportion of persons who developed ARDS in this study population is high compared to previous investigations. This might be due to the fact, that only hospitalized persons were included. A continuous rhythm monitoring providing data for real-time analysis of DC would be desirable. This could improve the ability for risk prediction of this patient collective. Third, calculation of DC can only be performed in the presence of sinus rhythm. Persons with either atrial fibrillation or permanent stimulation by a pacemaker need to be excluded. It should further be noted that ARDS has cofounders such as CHF which is a risk factor for a severe course of COVID-19 itself. DC may serve as an indicator of poor prognosis in persons with both COVID-19 as well as CHF.

To conclude, this is the first study of biosignal analysis in hospitalized persons with ARDS secondary to COVID-19. DC seems to be a convenient and promising prognostic tool that may identify persons with advanced COVID-19 that could develop ARDS.

**Declaration of Competing Interest**

Previously, we submitted an interim analysis of impaired cardiac function in COVID-19 positive persons to a different journal, which has been accepted for publication on May 28th (Rath D, Petersen-Uribe A, Avdiu A, et al. Impaired cardiac function is associated with mortality in persons with acute COVID-19 infection. Clin Res Cardiol. 2020;1:9). However, the endpoint in this subanalysis differed and fewer persons were enrolled. Furthermore, additional biosignal analyses from 24 h ECG Holter recordings were performed in the current manuscript.

**Funding**

This project was supported by the German Research Foundation (DFG) KFO-274 – Project Number 190538538, by the German Research Foundation (DFG) – Project Number 374031971 – TRR 240, funded by the German Research Foundation (DFG) – Project Number 335549539 – GRK2381.

**Ethics approval and consent to participate**

The study was approved by the local Ethics Committee (238/2018BO2) and complies with the declaration of Helsinki and the Good Clinical Practice Guidelines. Written informed consent was obtained from all persons or their legal representatives.

**Consent for publication**

The authors declare that they agree to the publication of this article.

**Availability of data and material**

The datasets analyzed during the present study are available from the corresponding author on reasonable request.

**References**

1. Yuki K, Fujioji M, Koutosogiani S. COVID-19 pathophysiology: a review. Clin Immunol. 2020;215:108427.
2. Cevik M, Bamford C, Ho A. COVID-19 pandemic – a focused review for clinicians. Clin Microbiol Infect. 2020;26(7):842–847.
3. Richardson S, Hirsch J, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059.
4. Haimovic A, Ravindra NG, Stoytchev S, Young HP, PerryWilson F, van Dijk D, et al. Development and validation of the quick COVID-19 severity index (qC5): a prognostic tool for early clinical decompensation. Ann Emerg Med. 2020;76(4):442–453.
5. Wyman L, Van Calster B, Bonten MMJ, Collins GS, Debray TPA, De Vos M, et al. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. BMJ. 2020;369:m1328.
6. Bauer A, Kantelhardt JW, Barthel P, Schneider R, Makikalillo T, Ulm K, et al. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet. 2006;367(9523):1674–1681.
7. Boehm K, Duckheim M, Mizera L, Grogga-Bada P, Malek N, Kreth F, et al. Heart rate variability for rapid stratification of emergency patients with malignant disease. Support Care Cancer. 2018;26(9):3289–3296.
8. Cygankiewicz I, Zareba W, Vazquez R, Valvirdu M, Gonzalez-Juanaetey JR, Valdes M, et al. Heart rate turbulence predicts all-cause mortality and sudden death in congestive heart failure patients. Heart Rhythm. 2008;5(8):1095–1102.
9. Duckheim M, Bensch C, Krititz L, Gotz N, Klee K, Grogga-Bada P, et al. Deceleration capacity of heart rate predicts 1-year mortality of patients undergoing transcatheter aortic valve implantation. Clin Cardiol. 2017;40(10):915–924.
10. Duckheim M, Klee K, Gotz N, Helle P, Grogga-Bada P, Mizera L, et al. Deceleration capacity as a risk predictor in patients presenting to the emergency department with syncope: a prospective exploratory pilot study. Medicine. 2017;96(49):e6805. [Baltimore].
11. Mizera L, Boehm K, Duckheim M, Grogga-Bada P, Gawaz M, Zuern CS, et al. Autonomic nervous system activity for risk stratification of emergency patients with pneumonia. J Emerg Med. 2018;55(4):472–480.
12. Eick C, Rizas KD, Meyer-Zurn CS, Grogga-Bada P, Hammi W, Kreth F, et al. Autonomic nervous system activity as risk predictor in the medical emergency department: a prospective cohort study. Crit Care Med. 2015;43(5):1079–1086.
13. Duckheim M, Gaebler M, Mizera L, Schriew C, Poli S, Zieman U, et al. Deceleration capacity for rapid risk stratification in patients suffering from acute ischemic stroke: a prospective exploratory pilot study. Medicine. 2021;100(13):e25333. [Baltimore].
14. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–689.
15. World medical association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc Res. 1997;35(1):2–3.
16. ICH harmonised tripartite guideline: guideline for good clinical practice. J Postgrad Med. 2001;47(3):199–203.
17. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions
of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Med Etika Bioet. 2002;9(1-2):12–19.

18. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526–2533.

19. Fuentes S, Chowdhury YS. Fraction of Inspired Oxygen (FiO2). StatPearls [Internet]; 2020.

20. Eick C, Rizas KD, Zuerer CS, Bauer A. Automated assessment of cardiac autonomic function by means of deceleration capacity from noisy, nonstationary ECG signals: validation study. Ann Noninvasive Electrocardiol. 2014;19(2):122–128.

21. Hamm W, Stulpnagel L, Vdovin N, Schmidt G, Rizas KD, Bauer A. Risk prediction in post-infarction patients with moderately reduced left ventricular ejection fraction by combined assessment of the sympathetic and vagal cardiac autonomic nervous system. Int J Cardiol. 2017;249:1–5.

22. Lian J, Wang L, Muessig D. A simple method to detect atrial fibrillation using RR intervals. Am J Cardiol. 2011;107(10):1494–1497.

23. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.

24. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666–1687.

25. Khanlali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19 – a systematic review. Life Sci. 2020;254:117788.